Metabolic dysfunction–associated steatotic liver disease (MASLD) has become the leading cause of chronic liver disease in pediatric populations, reflecting ...

Direct-to-consumer devices promising pain relief are flooding the market. Is there enough evidence to recommend these devices to patients with chronic pain?

An executive order issued by the Trump Administration last month declares that NASA will now operate as an intelligence and ...

Somerlot v. Jung, strengthens the enforceability of forum-selection clauses in contracts with implications beyond the medical ...

Making a noteworthy insider sell on September 24, DAVID THOMAS HULL III, President at Kewaunee Scientific (NASDAQ: KEQU), is reported in the latest SEC filing.

Natural products have long been recognized as a prolific source of bioactive compounds, offering substantial therapeutic promise for managing chronic ...

Chilean oranges will soon make their debut in Mexico. The South American is a new supplier in a market dominated by US fresh ...

As pharmaceutical companies shift their focus to specialty care, primary care remains at the vanguard of the fight against ...

Prime Medicine has surged over 130% in three months, driven by pipeline progress and visibility from recent scientific ...

DAVID THOMAS HULL III, President at Kewaunee Scientific (KEQU) , executed a substantial insider sell on September 22, according to an SEC filing. What Happened: A Form 4 filing from the U.S.